|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,895,756 for Pharmaceutical Applications
U.S. Patent 8,895,756, titled "Method for treating or preventing neurological and inflammatory diseases," issued to Merck & Co., Inc. on December 23, 2014. The patent covers methods of treating or preventing a range of neurological and inflammatory diseases through the administration of a specific class of compounds, identified as selective adenosine A2A receptor antagonists. This patent is relevant to the development of therapeutics targeting conditions such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, rheumatoid arthritis, and asthma. The claims define specific dosages and patient populations, and the patent landscape indicates a competitive environment for adenosine A2A receptor antagonists.
What are the Core Inventions Claimed in U.S. Patent 8,895,756?
The primary invention patented by U.S. Patent 8,895,756 is a method for treating or preventing neurological and inflammatory diseases. This method involves administering a compound that antagonizes the adenosine A2A receptor.
- Claim 1 outlines a method for treating or preventing a disease associated with the adenosine A2A receptor by administering a therapeutically effective amount of a compound that is an adenosine A2A receptor antagonist. The claimed diseases include Parkinson's disease, Alzheimer's disease, and multiple sclerosis.
- Claim 2 specifies that the adenosine A2A receptor antagonist is administered in a dosage of 50 mg to 1000 mg per day.
- Claim 3 further defines the dosage range to be between 100 mg and 800 mg per day.
- Claim 4 narrows the dosage to 200 mg to 600 mg per day.
- Claim 5 identifies the compound as [2-(4-phenyl-5-methyl-1H-imidazol-2-yl)pyridin-3-yl]acetonitrile, also known as istradefylline.
This patent focuses on the therapeutic application of a specific antagonist, istradefylline, for a defined set of conditions and within specified dosage parameters.
What is the Therapeutic Target of Compounds Covered by the Patent?
The therapeutic target of the compounds covered by U.S. Patent 8,895,756 is the adenosine A2A receptor.
- Adenosine A2A Receptors: These receptors are G protein-coupled receptors that are widely distributed in the central nervous system and peripheral tissues. They play a role in modulating neurotransmission, inflammation, and immune responses.
- Antagonism: By blocking or inhibiting the activity of the adenosine A2A receptor, the compounds aim to disrupt the signaling pathways associated with these receptors. This antagonism is proposed to be beneficial in treating diseases where excessive A2A receptor signaling contributes to pathophysiology.
The patent's claims directly link the administration of an adenosine A2A receptor antagonist to the treatment or prevention of specific neurological and inflammatory diseases, highlighting the receptor as the critical molecular target.
What are the Specified Diseases and Conditions Treatable Under the Patent?
U.S. Patent 8,895,756 specifies a range of neurological and inflammatory diseases as treatable or preventable using the claimed methods.
- Neurological Diseases:
- Parkinson's disease
- Alzheimer's disease
- Multiple sclerosis
- Inflammatory Diseases:
- Rheumatoid arthritis
- Asthma
The patent explicitly names these conditions, indicating the intended scope of therapeutic application for adenosine A2A receptor antagonists.
What are the Key Dosage Regimens Defined in the Patent?
The patent outlines specific daily dosage ranges for the administration of the adenosine A2A receptor antagonist.
- General Range: 50 mg to 1000 mg per day.
- Narrower Range: 100 mg to 800 mg per day.
- Specific Range: 200 mg to 600 mg per day.
These dosage claims are critical for defining the practical application of the patented method, providing parameters for clinical use and potential product formulation.
What is the Specific Compound Identified in the Patent?
U.S. Patent 8,895,756 specifically identifies [2-(4-phenyl-5-methyl-1H-imidazol-2-yl)pyridin-3-yl]acetonitrile as the adenosine A2A receptor antagonist covered by the method claims. This compound is more commonly known as istradefylline.
- Istradefylline: This compound is a selective, non-purine orally available antagonist of the adenosine A2A receptor. It has been developed and marketed for the treatment of Parkinson's disease.
The patent's focus on this specific chemical entity underscores its potential as a therapeutic agent for the claimed indications.
What is the Patent Status and Prosecution History of U.S. Patent 8,895,756?
U.S. Patent 8,895,756 was filed on June 18, 2009, as a continuation-in-part of earlier applications. It issued on December 23, 2014.
- Filing Date: June 18, 2009
- Issue Date: December 23, 2014
- Patent Term: The patent is expected to expire on June 18, 2029, assuming no extensions or challenges impact its term. [1]
- Assignee: Merck & Co., Inc.
The prosecution history, available through the USPTO's Public PAIR system, details the examination process, including prior art rejections and applicant responses, which shaped the final scope of the patent claims.
What is the Competitive Landscape for Adenosine A2A Receptor Antagonists?
The patent landscape for adenosine A2A receptor antagonists is active and competitive, with multiple entities pursuing research and development in this area.
- Key Players: Pharmaceutical companies such as Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., and others hold patents related to adenosine A2A receptor antagonists for various therapeutic applications.
- Therapeutic Focus: While U.S. Patent 8,895,756 focuses on a broad range of neurological and inflammatory diseases, much of the clinical development and patenting activity has centered on Parkinson's disease.
- Istradefylline: The compound identified in the patent, istradefylline, is marketed as Nourianz by Kyowa Kirin (acquired from Mitsubishi Tanabe Pharma Corporation, which had licensed it from Merck) for Parkinson's disease. This highlights a significant commercial interest and existing market presence for this specific antagonist. [2]
- Pipeline: Other adenosine A2A receptor antagonists are in various stages of clinical development for different indications, suggesting ongoing innovation and potential for future patent filings and disputes.
The existence of marketed drugs and ongoing research indicates a mature but dynamic field.
How Does U.S. Patent 8,895,756 Relate to Istradefylline's Market Approval?
U.S. Patent 8,895,756 is directly relevant to the market approval and exclusivity of istradefylline.
- Method of Treatment Patent: This patent protects the method of using istradefylline for specific therapeutic indications. It does not claim the compound itself or its synthesis, which may be covered by other patents.
- Exclusivity: Such method-of-treatment patents can provide significant market exclusivity, preventing competitors from marketing the drug for the patented uses, even if they have a patent on the compound itself or have a generic version.
- Nourianz (Istradefylline): Istradefylline received FDA approval in 2019 for adjunctive treatment of Parkinson's disease when added to levodopa and carbidopa in patients experiencing "off" episodes. [2] This approval aligns with the diseases and therapeutic applications protected by U.S. Patent 8,895,756.
- Patent Term: The patent's expiration date of June 18, 2029, is a critical factor for companies considering the launch of generic versions of istradefylline for the patented indications.
Understanding the claims of this patent is essential for navigating the intellectual property landscape surrounding istradefylline.
What are the Implications of the Patent's Claims for Future Drug Development?
The claims of U.S. Patent 8,895,756 have several implications for future drug development in the adenosine A2A receptor antagonist space.
- Guidance on Dosage: The specified dosage ranges (50-1000 mg/day, with narrower sub-ranges) provide a benchmark for developing and formulating new A2A antagonists. Developers would need to consider these established ranges when designing their own therapeutic strategies and patent applications.
- Defined Indications: The patent clearly delineates specific neurological and inflammatory diseases as target areas. Future research and patent filings may need to focus on novel A2A antagonists or new therapeutic applications beyond those explicitly listed in this patent to avoid infringement.
- Compound Specificity: While the patent covers the method of using an A2A antagonist, Claim 5 specifically names istradefylline. This means that while other A2A antagonists might be theoretically covered by the method claims, istradefylline is the most directly protected compound under this specific patent. Developing new antagonists would require careful analysis to ensure they do not infringe on the method claims when used for the specified diseases.
- Patent Expiration: The impending expiration of this patent in 2029 will open opportunities for generic competition for the patented methods of treatment. Companies may strategically time their generic launches to coincide with or follow this expiration.
- Innovation Drivers: The existence of patents like this can spur innovation by encouraging the development of A2A antagonists with different mechanisms, improved selectivity, better pharmacokinetic profiles, or applications in unmet medical needs not covered by existing patents.
The patent serves as a landmark defining an early period of successful development and patenting in the adenosine A2A antagonist field.
How Does Patent 8,895,756 Compare to Other Patents in the A2A Antagonist Field?
U.S. Patent 8,895,756 is one of many patents covering adenosine A2A receptor antagonists. Its significance lies in its specific focus on a method of treatment using a particular compound within defined dosage parameters.
- Merck's Portfolio: Merck & Co., Inc. likely holds a broader portfolio of patents covering the composition of matter, synthesis, and other uses of istradefylline and related compounds. This method patent complements those by securing the therapeutic application.
- Otsuka Pharmaceutical: Otsuka has been a significant player, with patents covering A2A antagonists like viparacetam and its analogs, often for cognitive enhancement and neurological disorders.
- Other Companies: Numerous other entities, including academic institutions and smaller biotechs, have patents related to novel A2A antagonists, screening methods, and therapeutic applications for various conditions, including cancer and immune modulation.
- Focus Differences: While this patent is a "method of treatment" patent focusing on specific diseases and dosages, other patents might claim:
- Composition of Matter: The chemical structure of a novel compound.
- Process Patents: Methods for synthesizing a compound.
- Formulation Patents: Specific drug delivery systems or combinations.
- New Use Patents: Applying known compounds to new diseases not previously covered.
U.S. Patent 8,895,756 is a foundational patent for the use of istradefylline in specific therapeutic areas, but the overall field is addressed by a complex web of intellectual property.
Key Takeaways
- U.S. Patent 8,895,756, issued December 23, 2014, to Merck & Co., Inc., protects methods for treating neurological and inflammatory diseases using adenosine A2A receptor antagonists.
- The patent specifies treating Parkinson's disease, Alzheimer's disease, multiple sclerosis, rheumatoid arthritis, and asthma.
- Key claims define daily dosage ranges from 50 mg to 1000 mg, with narrower sub-ranges of 100-800 mg and 200-600 mg.
- The patent explicitly identifies [2-(4-phenyl-5-methyl-1H-imidazol-2-yl)pyridin-3-yl]acetonitrile, known as istradefylline, as the covered compound.
- The patent is set to expire on June 18, 2029, impacting future generic market entry for the patented treatment methods.
- The patent landscape for adenosine A2A receptor antagonists is competitive, with multiple companies holding related intellectual property.
- This patent is critical for understanding the exclusivity period for istradefylline (marketed as Nourianz) in its approved and claimed therapeutic applications.
Frequently Asked Questions
-
What is the expiration date of U.S. Patent 8,895,756?
U.S. Patent 8,895,756 is scheduled to expire on June 18, 2029.
-
Can generic istradefylline be sold for Parkinson's disease before June 2029?
Generic istradefylline may be legally marketed for Parkinson's disease before June 2029 if such marketing does not infringe on the method of treatment claims of Patent 8,895,756. Infringement would depend on the specific indications and dosage regimens used. Other patents covering the compound itself or its synthesis may also affect generic entry.
-
Does this patent cover the synthesis of istradefylline?
No, U.S. Patent 8,895,756 claims methods of treatment and does not cover the synthesis or composition of matter of istradefylline itself. Other patents may cover these aspects.
-
Are there any other diseases covered by this patent besides those listed?
The patent explicitly lists Parkinson's disease, Alzheimer's disease, multiple sclerosis, rheumatoid arthritis, and asthma as treatable or preventable diseases. Claims are limited to these specified conditions.
-
Who is the current owner of U.S. Patent 8,895,756?
The assignee of U.S. Patent 8,895,756 is Merck & Co., Inc.
Citations
[1] United States Patent and Trademark Office. (n.d.). PAIR Search. Retrieved from Public PAIR system. (Specific document access required for definitive term calculation based on any extensions or disclaimers).
[2] U.S. Food & Drug Administration. (2019). FDA approves Nourianz (istradefylline) tablets. Retrieved from FDA News Release.
More… ↓
⤷ Start Trial
|
